The most commonly reported problem is skin irritation redness, itching, or a mild rash where the patch sits, particularly with prolonged use or if the adhesive contacts sensitive skin
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC
How soon will I feel the effects of retatrutide after my first injection
With Digbi GLP-Fit, the gut microbiome is monitored every 120 days
GLP-1 17,1%, 22,7%, 12,2%